Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease
ALDXLEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for the reproxalap New Drug Application (NDA) for the treatment of dry eye disease. The extended PDUFA target action date is March 16, 2026. Fol
Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
ALDX(NASDAQ:ALDX) LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. Dr. Brady’s conversation with Matthew Caufield, Director, Eq
Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma
ALDXLEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan Designation for ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of primary large B-Cell lymphomas of immune-privileged sites, including primary vitreoretinal lymphoma. There is currently no approved treatment for patients with primary vitreoretinal lymphoma, a rare, aggressive, high-grade cancer that affects appr
Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa
ALDXLEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of retinitis pigmentosa. There is currently no approved treatment for patients with most forms of retinitis pigmentosa, a clinical group of rare genetic eye diseases characterized by retinal cell death and loss of vision. Retinitis pigmen
Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
ALDXLEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025. Dr. Brady’s conversation with Matthew Caufield, Director, E
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
ALDXLEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune‑mediated and metabolic diseases, today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease. Per FDA agreement, the only
HC Wainwright & Co. Reiterates Buy on Aldeyra Therapeutics, Maintains $10 Price Target
ALDX12 Health Care Stocks Moving In Tuesday's Pre-Market Session
ALDXAldeyra Therapeutics To Announce Topline Results From Phase 3 Dry Eye Disease Clinical Trials Of Reproxalap At Conference Call Scheduled On May 6, 2025
ALDX10 Health Care Stocks Whale Activity In Today's Session
ALDXBTIG Maintains Buy on Aldeyra Therapeutics, Lowers Price Target to $9
ALDXHC Wainwright & Co. Reiterates Buy on Aldeyra Therapeutics, Maintains $10 Price Target
ALDX11 Health Care Stocks Moving In Thursday's Intraday Session
ALDXCrude Oil Dips 7%; ISM Services PMI Falls In March
ALDXDow Tumbles Over 1,100 Points; US Initial Jobless Claims Fall
ALDXFDA Rejects Aldeyra's Reproxalap For Dry Eye Disease Again, Citing Efficacy Concerns
ALDXThe FDA rejected Aldeyra's resubmission for reproxalap, citing efficacy concerns. The company plans another trial and aims to resubmit the NDA by mid-2025.
Aldeyra Therapeutics Receives Complete Response Letter From The U.S. FDA For The Reproxalap New Drug Application For The Treatment Of Signs And Symptoms Of Dry Eye Disease
ALDX12 Health Care Stocks Moving In Thursday's Pre-Market Session
ALDXHC Wainwright & Co. Reiterates Buy on Aldeyra Therapeutics, Maintains $10 Price Target
ALDXMarket-Moving News for November 18th
ALDXAldeyra Therapeutics Announces FDA Acceptance For Review Of The Resubmitted New Drug Application For Reproxalap In Treatment Of Dry Eye Disease; Based On FDA Acceptance, Co. Announces Expansion Of Option Agreement With AbbVie
ALDXAldeyra Therapeutics Announces Receipt Of Minutes From Dry Eye Disease Pre-NDA Meeting With FDA tones
ALDXHow To Attend Aldeyra Therapeutics Q1 2022 Earnings Conference Call
ALDXAldeyra Therapeutics (NASDAQ:ALDX) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results.
Aldeyra Therapeutics CFO Joshua Reed To Resign; Bruce Greenberg Appointed Interim CFO
ALDX